<DOC>
	<DOCNO>NCT02155725</DOCNO>
	<brief_summary>The purpose study assess benefit therapeutic strategy associate early administration human fibrinogen concentrate management PPH reduction bleed initiation prostaglandin intravenous infusion , follow vaginal delivery .</brief_summary>
	<brief_title>Fibrinogen Haemorrhage Delivery</brief_title>
	<detailed_description>Randomised , double-blind , multicenter , placebo-controlled study</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<criteria>Signed date informed consent form Vaginal delivery PPH require IV administration prostaglandin At least one available result Hb level third trim pregnancy 18yearold female patient older Covered healthcare insurance accordance local requirement Caesarean section Haemostatic intervention ( ligation , embolization hysterectomy ) already decide time inclusion Known placenta praevia accreta Hb level &lt; 10g/dl third trim pregnancy History venous arterial thromboembolic event Known inherit bleed thrombotic disorder Treatment lowmolecularweight heparin ( LMWH ) within 24 hour prior inclusion Treatment acetylsalicylic acid within 5 day prior inclusion Treatment vitamin K antagonists within 7 day prior inclusion Administration fibrinogen concentrate within 48 hour prior inclusion Administration FFP , platelets unit prohaemostatic drug , tranexamic acid rFVIIa prothrombin complex concentrate ( PCC ) within 48 hour prior inclusion Administration RBCs within 3 month prior inclusion Participation another interventional clinical study within 30 day prior inclusion Previous inclusion/enrolment present clinical study Known history hypersensitivity severe reaction component ClottafactÂ® placebo Minors , major guardianship , person stay health social institute people deprive freedom Known drug alcohol abuse Patients whose use concomitant medication may interfere interpretation data Any current significant medical condition might interfere treatment evaluation accord investigator 's judgement Patients unlikely survive treatment period evaluation Patients transfer another service</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PPH</keyword>
	<keyword>fibrinogen</keyword>
	<keyword>vaginal delivery</keyword>
</DOC>